uniQure (NASDAQ:QURE) Receives Consensus Recommendation of “Buy” from Analysts

uniQure (NASDAQ:QURE) has been given an average rating of “Buy” by the ten ratings firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $40.00.

A number of equities analysts recently issued reports on QURE shares. Stifel Nicolaus boosted their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Wednesday, December 11th. Finally, Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.74% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. lifted its holdings in shares of uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after buying an additional 752,889 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of uniQure during the third quarter worth $444,000. FMR LLC lifted its holdings in shares of uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after buying an additional 346,274 shares in the last quarter. Sanders Morris Harris LLC lifted its holdings in shares of uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after buying an additional 34,034 shares in the last quarter. Finally, Franklin Resources Inc. bought a new position in shares of uniQure in the third quarter worth $7,360,000. 78.83% of the stock is owned by institutional investors.

uniQure Price Performance

NASDAQ QURE opened at $15.74 on Monday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $767.21 million, a PE ratio of -3.17 and a beta of 0.41. The company has a 50 day moving average price of $13.90 and a two-hundred day moving average price of $8.98. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. As a group, equities analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.